



# Reducing transmission of COVID-19: Spotlight on vaccines

---

Fact sheet for COVID-19 vaccinations


For more information, visit [www.touchinfectiousdiseases.com](http://www.touchinfectiousdiseases.com)

# Classes of COVID-19 vaccines



Vaccination has prevented an estimated **14.4 million** (95% CrI 13.7–15.9) deaths due to COVID-19, representing a **79% reduction in deaths globally** during the first year of COVID-19 vaccination rollout\*<sup>1</sup>

## Common vaccine platforms<sup>2,3</sup>



\*8 Dec 2020 to 8 Dec 2021.

## Efficacy and safety of common\* COVID-19 vaccines<sup>4</sup>


Vaccine	Platform Manufacturer	Effectiveness at preventing: <sup>†</sup> (%)		Commonly reported (≥40%) local side effects
		Severe disease	Infection	
BNT162b2	mRNA vaccine Pfizer/BioNTech	72	44	<b>In participants ≥56 years old<sup>5</sup></b> Injection-site pain (78%), fatigue (57%) and headache (46%)
mRNA-1273	mRNA vaccine Moderna	73	48	<b>In participants ≥65 years old<sup>6</sup></b> Injection-site pain (88%), fatigue (65%), headache (53%), myalgia (52%) and arthralgia (40%)
AZD1222	Viral vector AstraZeneca/Oxford	71	36	<b>In participants ≥18 years old<sup>7</sup></b> Injection-site tenderness (68%), injection-site pain (58%), headache (53%), fatigue (53%), myalgia (44%) and malaise (44%)
Ad26.COV2.S	Viral vector Johnson & Johnson	57	33	<b>In participants ≥18 years old<sup>8</sup></b> Injection-site pain (54%), fatigue (44%) and headache (43%)
CoronaVac	Inactivated virus Sinovac	37	24	<b>In participants 18–59 years old<sup>9</sup></b> Injection-site pain (40%)
BBIBP-CorV	Inactivated virus Sinopharm	53	35	<b>In participants &gt;49 years old<sup>10</sup></b> Injection-site pain (42%)

\*Vaccines with the most doses administered globally (according to Our World In Data)<sup>11</sup> that have also obtained EUL by WHO<sup>12</sup>;


<sup>†</sup>BA.5/Omicron. The Omicron variant and subvariants are currently (as of March 2023 according to Our World In Data) the predominant variants of COVID-19 circulating, although this is subject to change.

# Increasing vaccine coverage<sup>13-15</sup>

## Determinants of vaccine uptake



## Interventions shown to increase vaccination



## Abbreviations and references

### Abbreviations

CrI, credible interval; EUL, emergency use listing; mRNA, messenger ribonucleic acid; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SBC, social and behaviour change; WHO, World Health Organization.

### References

1. Watson OJ, et al. *Lancet Infect Dis*. 2022;22:1293–302.
2. Eroglu B, et al. *Vaccines (Basel)*. 2021;10:62.
3. Al-Jighefee HT, et al. *Vaccines (Basel)*. 2021;9:1196.
4. Health data. COVID-19 vaccine efficacy summary. Available at: <http://bit.ly/3Z1Z4wL> (accessed 16 March 2023).
5. FDA. BNT162b2 PI. Available at: <https://bit.ly/3Z62TRf> (accessed 16 March 2023).
6. FDA. mRNA-1273 PI. Available at: <https://bit.ly/3ZZrtEZ> (accessed 16 March 2023).
7. EMA. AZD1222 SmPC. Available at: <https://bit.ly/3lkqMH6> (accessed 16 March 2023).
8. EMA. Ad26.COVS.S SmPC. Available at: <https://bit.ly/3ldtWMV> (accessed 16 March 2023).
9. WHO. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19. Available at: <http://bit.ly/3YUBNg6> (accessed 16 March 2023).
10. Saeed BQ, et al. *Int J Infect Dis*. 2021;111:219–26.
11. Our World In Data. Available at: <http://bit.ly/3n6VxQi> (accessed 16 March 2023).
12. WHO. Emergency use listing. Available at: <http://bit.ly/3FGt2iN> (accessed 16 March 2023).
13. Thomson A, et al. *Vaccine*. 2016;34:1018–24.
14. WHO. *Weekly Epidemiological Record*. No 20. 2022;97:209–24.
15. Kassianos G, et al. *Drugs Context*. 2021;10:2020–9–5.

The guidance provided by this practice aid is not intended to directly influence patient care. Clinicians should always evaluate their patients' conditions and potential contraindications, and review any relevant manufacturer product information or recommendations of other authorities prior to consideration of procedures, medications, or other courses of diagnosis or therapy included here.

Our practice aid coverage does not constitute implied endorsement of any product(s) or use(s). touchINFECTIOUS DISEASES cannot guarantee the accuracy, adequacy or completeness of any information, and cannot be held responsible for any errors or omissions.